Muraglitazar


Muraglitazar
Systematic (IUPAC) name
2-[(4-Methoxyphenoxy)carbonyl-[ [4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid
Identifiers
CAS number	331741-94-7
ATC code	?
PubChem	206044
Chemical data
Formula	C₂₉H₂₈N₂O₇
Mol. mass	516.54
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Muraglitazar (proposed tradename Pargluva) is a peroxisome proliferator-activated receptor agonist.^[1]

The drug had completed phase III clinical trials,^[2] however in May, 2006 Bristol-Myers Squibb announced that it had discontinued further development.^[3]

[edit] References

^ Waites CR, Dominick MA, Sanderson TP, Schilling BE (2007). "Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist". Toxicol. Sci. 100 (1): 248-58. doi:10.1093/toxsci/kfm193. PMID 17675651.
^ Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA (2006). "Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study". Diabetes Care 29 (5): 1016-23. doi:10.2337/diacare.2951016. PMID 16644631.
^ Bristol-Myers Squibb Announces Discontinuation of Development of Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes. Bristol-Myers Squibb (2006-05-18). Retrieved on 2008-03-18.

v • d • e Oral antidiabetic drugs and Insulin analogs (A10)

Biguanides	Metformin

Sulfonylureas	Carbutamide, Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide

Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose

Thiazolidinediones (TZD)	Pioglitazone, Rivoglitazone^†, Rosiglitazone, Troglitazone^‡

Meglitinides	Nateglinide, Repaglinide, Mitiglinide

Dipeptidyl peptidase-4 (DPP-4) inhibitors	Alogliptin^†, Saxagliptin^†, Sitagliptin, Vildagliptin

Glucagon-like peptide-1 analog	Exenatide, Liraglutide^†, Albiglutide^†

Amylin analog	Pramlintide

Insulin analogs	fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir), Inhalable insulin (Exubera)

Dual PPAR agonists	Aleglitazar^†, Muraglitazar^§, Tesaglitazar^§

SGLT2 inhibitor	Dapagliflozin^†, Remogliflozin^†

^†Undergoing clinical trials. ^‡ Withdrawn from market. ^§Development halted.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.